Emmed Research

Running trials

• Recruiting

  A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

  NCT07298421· Phase 3· Source

• Recruiting

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

  NCT07613307· Phase 3· Source

• Recruiting

  A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07598396· Phase 2· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Source

• Active, not recruiting

  A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

  NCT06966479· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· Phase 3· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting
• Lupus (SLE)1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Source